HOTAIR induces EGFR-TKIs Resistance in Non-Small Cell Lung Cancer through Epithelial-Mesenchymal Transition

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) rechallenged therapy for EGFR-mutant NSCLC patients who acquired resistance showed moderate efficacy[1,2]. Nevertheless, the majority of NSCLC patients gradually acquire resistance over 6-18.9 months of therapy. Notably, approximately 30% of NSCLC patients with EGFR mutations develop primary resistance EGFR-TKIs[3 –5]. Hence, it is of great importance to explore the exact mechanism of EGFR-TKIs resistance, along with identification of solutions to battle the resistance[6].

Source: Lung Cancer - July 1, 2020 Category: Cancer & Oncology Authors: Qi Wang, Xuefei Li, Shengxiang Ren, Chunxia Su, Chunyu Li, Wei Li, Jia Yu, Ningning Cheng, Caicun Zhou Source Type: research